Abstracts tagged "Cancer"

Abstract Number: 2143 • 2018 ACR/ARHP Annual Meeting
Lymphoproliferative Malignancy in Psoriatic Arthritis and the Role of Systemic Immunosuppressive Therapies
Linh Truong¹ and Maida Wong², ¹Internal Medicine, University of California, Irvine, Orange, CA, ²Division of Rheumatology, University of California, Irvine, Orange, CA
Background/Purpose: Psoriatic arthritis (PsA) is a systemic inflammatory disease that can have musculoskeletal (PsA-MsK) or concurrent MsK and skin (PsA-MsK/skin) manifestations, and the skin disease…
Abstract Number: 2160 • 2018 ACR/ARHP Annual Meeting
Effect of the Metabolic Syndrome on Incident Vascular Events and Mortality in Four Rheumatic Diseases: An 8-Year Longitudinal Analysis
Chi Chiu Mok¹, Chiu Sum Chu¹, Ling Yin Ho², Kar Li Chan¹, Sau Mei Tse¹ and Chi Hung To³, ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Dept of Medicine, Tuen Mun Hospital, Hong Kong SAR, Hong Kong, ³Medicine, Pok Oi Hospital, Hong Kong, Hong Kong
Background/Purpose: To study the effect of the metabolic syndrome (MetS) on incident vascular events and mortality in 4 rheumatic diseases over an 8-years’ follow-up. Methods:…
Abstract Number: 2991 • 2018 ACR/ARHP Annual Meeting
Malignancies In Giant Cell Arteritis- A Population-Based Cohort Study
Pavlos Stamatis¹, Carl Turesson², Minna Willim³, Jan-Åke Nilsson⁴, Martin Englund⁵ and Aladdin Mohammad⁶, ¹Clinical Sciences, Rheumatology Lund, Lund University, Lund, Sweden, ²Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ³Rheumatology, Department of Clinical Sciences, Lund, Lund University, Lund, Sweden, ⁴Department of Rheumatology, Skåne University Hospital, Malmö, Sweden, ⁵Clinical Sciences Lund, Clinical Epidemiology Unit, Lund University, Lund, Sweden, ⁶Department of Medicine, University of Cambridge, Cambridge, United Kingdom
Background/Purpose: To investigate the cancer risk in patients with biopsy-proven giant cell arteritis (GCA). Methods: The study population consisted of 830 patients (74 % women)…
Abstract Number: 364 • 2018 ACR/ARHP Annual Meeting
Elevated sCD40L As a Predictive Biomarker of Immune-Related Adverse Events in Patients Receiving Immune Checkpoint Inhibitors
Nicholas Meti¹, Khashayar Esfahani^1,2, Ines Colmegna^1,3, Marvin J. Fritzler⁴, Nathalie A. Johnson^1,5, Ciriaco Piccirillo^1,6, Wilson H. Miller Jr.^1,2 and Marie Hudson^1,7, ¹Department of Medicine, McGill University, Montreal, QC, Canada, ²Department of Oncology, McGill University, Jewish General Hospital, Rossy Cancer Network, Montreal, QC, Canada, ³Division of Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ⁴Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁵Division of Hematology, Jewish General Hospital, Montreal, QC, Canada, ⁶Department of Microbiology & Immunology, McGill University, Montreal, QC, Canada, ⁷Division of Rheumatology, Jewish General Hospital, Montreal, QC, Canada
Background/Purpose: The clinical use of immune checkpoint inhibitors (ICI) has led to outstanding clinical outcomes in previously refractory cancers, but ICI have also been associated…
Abstract Number: 710 • 2018 ACR/ARHP Annual Meeting
An Analysis of Cell-of-Origin in Diffuse Large B-Cell Lymphoma in Systemic Lupus Erythematosus, Including Molecular and Clinical Factors Associated with Survival
Basile Tessier-Cloutier¹, David Twa², Eva Baecklund³, Randy Gascoyne⁴, Nathalie A. Johnson⁵, Carin Backlin³, Diane L. Kamen⁶, Ann E. Clarke⁷, Rosalind Ramsey-Goldman⁸, Jennifer LF Lee⁹, Pedro Farinha⁴ and Sasha Bernatsky¹⁰, ¹Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada, ²Department of Medicine, University of British Columbia, Vancouver, BC, Canada, ³Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ⁴Department of Pathology, British Columbia Cancer Agency, Vancouver, BC, Canada, ⁵Department of Oncology, McGill University, Montreal, QC, Canada, ⁶Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ⁷Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁸FSM, Northwestern University, Chicago, IL, ⁹Medicine, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ¹⁰Divisions of Rheumatology and Clinical Epidemiology, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) is associated with increased risk of diffuse large B-cell lymphoma (DLBCL). DLBCL is routinely classified by cell-of-origin (COO), with non-germinal…
Abstract Number: 814 • 2018 ACR/ARHP Annual Meeting
NON Diffuse SSc, Peripheral Neuropathy, Concomitant Sjogren Syndrome and ANTI-RNA Polymerase III Represent Risk Factors for the Higher Frequency of Cancer in a Large Single Cohort of Patients with Systemic Sclerosis
Ana Paula Luppino-Assad¹, Adriana Bortoluzzo², Henrique Carriço da Silva³, Danieli Andrade⁴ and Percival Sampaio-Barros⁴, ¹Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR., sao paulo, Brazil, ²c Instituto Insper de Educação e Pesquisa, São Paulo, SP, Brasil, sao paulo, Brazil, ³Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR., SAO PAULO, Brazil, ⁴Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR., São Paulo, Brazil
Background/Purpose: A higher prevalence of cancer has been described in patients with systemic sclerosis (SSc), but the magnitude of this risk and the type of…
Abstract Number: 880 • 2018 ACR/ARHP Annual Meeting
Serum Cytokine and Chemokine Concentrations Predict Incident Cancer in US Veterans with Rheumatoid Arthritis
Bryant R. England¹, Harlan Sayles², Punyasha Roul², Apar Ganti³, Jeremy Sokolove⁴, William H. Robinson⁵, Grant W. Cannon⁶, Brian Sauer⁷, Joshua Baker⁸, Geoffrey M. Thiele² and Ted R. Mikuls⁹, ¹Rheumatology, VA Nebraska-Western Iowa Health Care System & University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Omaha, NE, ³VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha, NE, ⁴Division of Immunology and Rheumatology, Stanford University Medical Center, Mountain View, CA, ⁵Stanford University, Palo Alto, CA, ⁶Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ⁷Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ⁸Philadelphia VA Medical Center and University of Pennsylvania, Philadelphia, PA, ⁹VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE
Background/Purpose: The immune system plays a critical protective role in cancer (CA) development. Perturbations in immune signaling, including cytokine dysregulation, may disrupt this homeostatic balance.…
Abstract Number: 1522 • 2018 ACR/ARHP Annual Meeting
Time Dependent Effect of Biologic Therapy on Overall Survival in Patients with Rheumatoid Arthritis and Cancer
Xerxes Pundole¹, Natalia Zamora², Harish Siddhanamatha³, Jean Tayar⁴, Cheuk Hong Leung⁵, Heather Lin⁶ and Maria Suarez-Almazor⁷, ¹Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ²Reumatologia, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, Buenos Aires, Argentina, ³The University of Texas Health Science Center, School of Biomedical Informatics, Houston, TX, USA, Houston, TX, ⁴Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA, Houston, TX, ⁵Department of Biostatistics, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ⁶Biostatistics, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ⁷Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Background/Purpose: Biologic disease-modifying anti-rheumatic drugs (bDMARDs) are commonly used in the treatment of rheumatoid arthritis (RA). But the use of bDMARDs in patients with RA…
Abstract Number: 11L • 2017 ACR/ARHP Annual Meeting
Risk of Second Malignant Neoplasm and Mortality in Rheumatoid Arthritis Patients Treated with Biological Dmards: A Danish Population-Based Cohort Study
Lene Dreyer¹, René Cordtz², Inger Marie J. Hansen³, Lars Erik Kristensen⁴, Merete Lund Hetland⁵ and Lene Mellemkjær⁶, ¹Center for Rheumatology and Spine Diseases, Gentofte University Hospital,Rigshospitalet, Hellerup, Denmark, ²Center for Rheumatology and Spine Diseases, Gentofte University Hospital, Rigshospitalet, Hellerup, Denmark, ³Department of Reumatology, OUH, Svendborg Hospital, Svendborg, Denmark, ⁴The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen F, Denmark, ⁵DANBIO, Glostrup Hospital.On behalf of all Depts of Rheumatology in Denmark.Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Glostrup, Denmark, ⁶Danish Cancer Society Research Center, Copenhagen, Denmark, Copenhagen, Egypt

Background/Purpose: The safety of treatment with biological DMARDs (bDMARDs) has been carefully studied for the past 15 years, however, it is still largely unknown whether…
Abstract Number: 849 • 2017 ACR/ARHP Annual Meeting
Tumor TIF1 Mutations and Loss of Heterozygosity Related to Cancer Associated Myositis
Iago Pinal-Fernandez¹, Berta Ferrer-Fabregas², Ernesto Trallero-Araguas¹, Eva Balada¹, Maria Angeles Martinez³, Jose Cesar Milisenda⁴, Gloria Aparicio-Español⁵, Moises Labrador-Horrillo¹, Vicente Garcia-Patos¹, Josep Maria Grau-Junyent⁴ and Albert Selva O'Callaghan⁶, ¹Internal Medicine, Autoimmune Diseases Unit. Vall d´Hebron Hospital, Barcelona, Spain, ²Pathology, Vall d´Hebron, Barcelona, Spain, ³Immunology, Immunology Department, Barcelona, Spain, ⁴Muscle Research Group and Ciberer, Hospital Clinic Provincial, Barcelona, Spain, ⁵Dermatology, Vall d´Hebron Hospital, Barcelona, Spain, ⁶Internal Medicine, Hospital Universitari General Vall d'Hebron, Barcelona, Spain
Background/Purpose: To analyze the influence of genetic alterations and differential expression of the TIF1 genes in the pathophysiology of cancer-associated myositis (CAM). Methods: Whole exome…
Abstract Number: 853 • 2017 ACR/ARHP Annual Meeting
Anti-TIF-1 Antibody Positivity Is Associated with a Five-Fold Increase in Cancer Risk in the Idiopathic Inflammatory Myopathies
Alexander Oldroyd^1,2, Jamie C Sergeant^1,3, Paul New⁴, Neil J. McHugh^5,6, Zoe Betteridge⁵, Janine Lamb⁷, William Ollier⁷, Robert Cooper^4,7,8 and Hector Chinoy^2,9, ¹Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, ²NIHR Manchester Biomedical Research Centre, Central Manchester NHS Foundation Trust, Manchester, United Kingdom, ³Centre for Biostatistics, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁴MRC/ARUK Centre for Integrated Research into Musculoskeletal Ageing, University of Liverpool, Liverpool, United Kingdom, ⁵Department of Pharmacy and Pharmacology, The University of Bath, Bath, United Kingdom, ⁶Royal National Hospital for Rheumatic Diseases, Bath, UK, Bath, United Kingdom, ⁷Division of Population Health, Health Services Research and Primary Care, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁸Department of Rheumatology, Aintree University Hospital, Liverpool, United Kingdom, ⁹Department of Rheumatology, Salford Royal NHS Foundation Trust, Manchester Academic Health Science Centre, Salford, United Kingdom
Background/Purpose: There is an increased cancer risk associated with the idiopathic inflammatory myopathies (IIM). Studies have identified that positivity for the autoantibody against transcriptional intermediary…
Abstract Number: 1146 • 2017 ACR/ARHP Annual Meeting
Associations between Gout and Cancer in an Nhanes Cohort
Patricia Kachur¹, Venkatesh Gondhi², Yinjin Wert³ and Pramil Cheriyath², ¹Internal Medicine, Ocala Regional Medical Center, Ocala, FL, ²Ocala Regional Medical Center, Ocala, FL, ³Pinnacle Health System, Harrisburg, PA
Background/Purpose: Gout is the most common inflammatory disease in the United States (US), affecting more than 4% of the population. Although uric acid (UA) can…
Abstract Number: 1227 • 2017 ACR/ARHP Annual Meeting
Osteoporosis and Breast Cancer: Can FRAX-Based Risk Factors Accurately Predict Further Fractures at This Setting?
Salvador López-Salguero¹, Laura Ranieri², Juan Carlos Ordoñez³, Mariano Andrés^4,5, Jose Ponce⁶ and Isabel Ibero², ¹Sección de Reumatología, Hospital General Universitario de Alicante, Alicante, Spain, ²Reumatología, Dpt. Rheumatology, Hospital General Universitario Alicante, Alicante, Spain, ³RHEUMATOLOGY, Dpt. Rheumatology, Hospital General Universitario Alicante, Alicante, Spain, ⁴Dpt. Rheumatology, Hospital General Universitario Alicante, Alicante, Spain, ⁵Universidad Miguel Hernández, Elche, Spain, ⁶Oncología, Dpt. Oncology, Hospital General Universitario Alicante, Alicante, Spain
Background/Purpose: Women with breast cáncer (BC) are at risk for the development of bone loss and osteoporosis (OP) mainly due to adjuvant therapies, as aromatase…
Abstract Number: 1228 • 2017 ACR/ARHP Annual Meeting
Postmenopausal Breast Cancer Patients on Aromatase Inhibitor Therapy and Their Increased Risk of Fragility Fracture
Anna Lafian¹, Julia Suh² and Karina Torralba³, ¹Internal Medicine, Arrowhead Regional Medical Center, Colton, CA, ²Internal Medicine, Loma Linda University, Loma Linda, CA, ³Internal Medicine/Rheumatology, Loma Linda University, Loma Linda, CA
Background/Purpose: Postmenopausal women with breast cancer have higher osteoporosis risk due to declining estrogen levels and use of aromatase inhibitors (AIs). The American Society of…
Abstract Number: 1606 • 2017 ACR/ARHP Annual Meeting
Cancer in an SLE Inception Cohort: Smoking May out-Perform Tumor Markers As a Risk Predictor
Sasha Bernatsky¹, Murray Urowitz², John G Hanly³, Ann E. Clarke⁴, Marvin J. Fritzler⁵, Caroline Gordon⁶, Juanita Romero-Diaz⁷, Graciela S. Alarcón⁸, Sang-Cheol Bae⁹, Michelle Petri¹⁰, Joan T. Merrill¹¹, Daniel J. Wallace¹², Paul R. Fortin¹³, Dafna D Gladman¹⁴, David A. Isenberg¹⁵, Anisur Rahman¹⁶, Susan Manzi¹⁷, Ola Nived¹⁸, Gunnar K. Sturfelt¹⁹, Christine A. Peschken²⁰, Jorge Sanchez-Guerrero²¹, Guillermo Ruiz-Irastorza²², Cynthia Aranow²³, Ronald F van Vollenhoven²⁴, Asad Zoma²⁵, Kristján Steinsson²⁶, Munther A Khamashta²⁷, Ellen M. Ginzler²⁸, Anca Askanase²⁹, Kenneth C. Kalunian³⁰, Mary Anne Dooley³¹, S. Sam Lim³², Diane L. Kamen³³, Søren Jacobsen³⁴, Manuel Ramos-Casals³⁵, Murat Inanc³⁶, Jennifer LF Lee³⁷ and Rosalind Ramsey-Goldman³⁸, ¹Divisions of Rheumatology and Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²Centre for Prognosis Studies in the Rheumatic Diseases, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Division of Rheumatology, Department of Medicine and Department of Pathology, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada, ⁴Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ⁵Medicine, University of Calgary, Calgary, AB, Canada, ⁶Rheumatology Research Group, Institute of Inflammation and Ageing,, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ⁷Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico city, Mexico, ⁸University of Alabama at Birmingham, Birmingham, AL, ⁹Department of Rhematology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ¹⁰Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD, ¹¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹²Rheumatology, Cedars-Sinai Medical Center, Beverly Hills, CA, ¹³Université Laval, CHU de Québec, Québec, QC, Canada, ¹⁴Department of Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ¹⁵Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, ¹⁶Rayne Institute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom, ¹⁷Medicine, Allegheny Health Network, Pittsburgh, PA, ¹⁸Department of Rheumatology, University Hospital, Lund, Sweden, ¹⁹Department of Rheumatology, Univ Hospital Lund, Lund, Sweden, ²⁰RR 149G, Univ of Manitoba, Winnipeg, MB, Canada, ²¹Division of Rheumatology, Toronto Western Hospital, Toronto, AB, Canada, ²²Biocruces Health Research Institute, Barakaldo, Spain, ²³Autoimmune and Musculoskeletal Disease, The Feinstein Institute for Medical Research, Manhasset, NY, ²⁴AMC, F4-214, Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ²⁵University of Glasgow, Glaskow, United Kingdom, ²⁶Rheumatology, Univ. Hospital, Reykjavik, Iceland, ²⁷Lupus Research Unit, Lupus Research Unit, The Rayne Institute, King's College London School of Medicine, St Thomas' Hospital, London, United Kingdom, ²⁸Rheumatology, Division of Rheumatology, Department of Medicine, SUNY Downstate Medical Center, Brooklyn, NY, ²⁹Rheumatology, Columbia University, New York, NY, ³⁰Division of Rheumatology, Allergy & Immunology, UCSD School of Medicine Center for Innovative Therapy, La Jolla, CA, ³¹UNC Kidney Centre, Chapel Hill, NC, ³²Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, ³³Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ³⁴Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ³⁵Hospital Clinic, Barcelona, Spain, ³⁶Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ³⁷Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³⁸FSM, Northwestern University, Chicago, IL
Background/Purpose: We assessed incident cancers in a large inception SLE cohort, and examined demographic and clinical factors, including tumor-related autoantibodies against proliferating cell nuclear antigen…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].